Related Experiment Videos

Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line

L Ma1, C Gauvillé, Y Berthois

  • 1Laboratoire de Pharmacologie Expérimentale et Clinique, INSERM EP-9932, Institut de Génétique Moléculaire, Paris, France.

Oncogene
|December 22, 1999
PubMed

Insights

Amphiregulin (AR) drives breast cancer progression and tumor angiogenesis. Inhibiting AR in transformed breast cells significantly reduced tumor growth, mass, and vascularization in vivo, revealing its oncogenic role.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Epidermal Growth Factor (EGF) receptor family and ligands are key in breast cancer.
  • Transformed breast epithelial cells (NS2T2A1) exhibit increased tumorigenicity and higher expression of EGF receptors (EGFR) and amphiregulin (AR).

Purpose of the Study:

  • To investigate the tumorigenic role of amphiregulin (AR) in transformed breast epithelial cells.
  • To assess the effect of AR inhibition on malignant phenotypes in vitro and in vivo.

Main Methods:

  • Transfection of NS2T2A1 cells with AR antisense RNA (AR AS) to reduce AR protein expression.
  • Assessed anchorage-independent growth in vitro.
  • Evaluated tumor development, mass, and intra-tumoral vascularization in nude mice models.

Main Results:

  • AR AS cell lines showed significantly reduced AR protein expression.
  • Anchorage-independent growth was reduced in AR AS cell lines.
  • Tumorigenicity, tumor mass, and intra-tumoral vascularization were significantly decreased in vivo in AR AS cell lines.

Conclusions:

  • Amphiregulin (AR) exhibits oncogenic properties in transformed breast epithelial cells.
  • AR plays a critical role in breast tumor growth and angiogenesis.
  • Targeting AR represents a potential therapeutic strategy for breast cancer.

Related Concept Videos